Norton W T, Brosnan C F, Cammer W, Goldmuntz E A
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York 10461.
Acta Neurobiol Exp (Wars). 1990;50(4-5):225-35.
Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease of the central nervous system commonly used as a model for multiple sclerosis. In both of these diseases demyelination occurs association with perivascular infiltrates of T-cells and macrophages. The similarities in immunopathology suggest that these two diseases share common mechanisms of tissue destruction. We have proposed a general mechanism to explain the clinical and histopathological features of EAE. T-cells sensitized to the inducing antigen, myelin basic protein (MBP), react with antigen-presenting cells (possibly endothelial cells, microglia or astrocytes) in the central nervous system. As a consequence of this reaction, T-cells release lymphokines which activate macrophages, stimulate an augmenting inflammatory response, and, through the action of vasoactive amines, induce vasospasm and breakdown of the blood-brain barrier. The activated macrophages secrete inflammatory mediators, including plasminogen activator and other proteinases, which, in concert with serum plasminogen and complement, initiate myelin destruction. The macrophage products also serve to enhance the inflammatory response and vascular permeability. In support of this hypothesis we find that: (1) macrophage-secreted proteinases can degrade MBP in lyophilized myelin and that proteolysis is amplified in the presence of plasminogen; (2) proteolysis of proteins in fresh myelin by macrophage proteinases and plasminogen or by plasmin is potentiated by complement; (3) removal of macrophages from the circulation suppresses EAE; (4) proteinase inhibitors suppress EAE; and (5) prazosin, an alpha 1-adrenergic receptor antagonist, suppresses the clinical signs of EAE and the increased vascular permeability but only delays the inflammatory response. We believe that prazosin acts on the vascular alpha 1-adrenergic receptor to inhibit vasospasm and prevent opening of the blood-brain barrier. Thus it is possible to suppress both clinical signs and pathology by interceding at several steps of the cell-mediated immune reaction.
实验性自身免疫性脑脊髓炎(EAE)是一种中枢神经系统的炎性脱髓鞘疾病,通常用作多发性硬化症的模型。在这两种疾病中,脱髓鞘均与T细胞和巨噬细胞的血管周围浸润有关。免疫病理学上的相似性表明这两种疾病具有共同的组织破坏机制。我们提出了一种通用机制来解释EAE的临床和组织病理学特征。对诱导抗原髓鞘碱性蛋白(MBP)致敏的T细胞与中枢神经系统中的抗原呈递细胞(可能是内皮细胞、小胶质细胞或星形胶质细胞)发生反应。作为这种反应的结果,T细胞释放淋巴因子,激活巨噬细胞,刺激炎症反应增强,并通过血管活性胺的作用诱导血管痉挛和血脑屏障破坏。活化的巨噬细胞分泌炎性介质,包括纤溶酶原激活物和其他蛋白酶,它们与血清纤溶酶原和补体协同作用,引发髓鞘破坏。巨噬细胞产物还起到增强炎症反应和血管通透性的作用。为支持这一假说,我们发现:(1)巨噬细胞分泌的蛋白酶可降解冻干髓鞘中的MBP,并且在纤溶酶原存在的情况下蛋白水解作用增强;(2)巨噬细胞蛋白酶和纤溶酶原或纤溶酶对新鲜髓鞘中蛋白质的蛋白水解作用在补体存在时增强;(3)从循环中去除巨噬细胞可抑制EAE;(4)蛋白酶抑制剂可抑制EAE;(5)α1肾上腺素能受体拮抗剂哌唑嗪可抑制EAE的临床症状和增加的血管通透性,但仅延迟炎症反应。我们认为哌唑嗪作用于血管α1肾上腺素能受体以抑制血管痉挛并防止血脑屏障开放。因此,通过在细胞介导的免疫反应的多个步骤进行干预,可以抑制临床症状和病理变化。